<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712140</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000598391</org_study_id>
    <secondary_id>WMS-PERSEPHONE</secondary_id>
    <secondary_id>MREC-PERSEPHONE</secondary_id>
    <secondary_id>EUDRACT: 2006-007018-39</secondary_id>
    <secondary_id>ISRCTN 52968807</secondary_id>
    <secondary_id>MREC 07/MRE08/35</secondary_id>
    <secondary_id>EU-20858</secondary_id>
    <secondary_id>CRUK-BRD/07/137</secondary_id>
    <nct_id>NCT00712140</nct_id>
  </id_info>
  <brief_title>Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer</brief_title>
  <official_title>Persephone: Duration of Trastuzumab With Chemotherapy in Women With Early Stage Breast Cancer: Six Months Versus Twelve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warwick Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. It is not yet known which regimen&#xD;
      of trastuzumab is more effective in treating early breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is comparing two trastuzumab regimens to see how&#xD;
      well they work in treating women with HER2-positive early breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine disease-free survival of women with HER2-positive early breast cancer treated&#xD;
           with neoadjuvant or adjuvant trastuzumab (Herceptin®) for 6 months versus 12 months.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Determine the expected incremental cost effectiveness (cost per quality adjusted life&#xD;
           year gained) for 6 months versus 12 months trastuzumab.&#xD;
&#xD;
        -  Determine cardiac function as assessed by left ventricular ejection fraction every 3&#xD;
           months during treatment.&#xD;
&#xD;
        -  Analyze the predictive factors for development of cardiac damage.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to estrogen receptor&#xD;
      status (negative vs positive); chemotherapy timing (adjuvant vs neoadjuvant); chemotherapy&#xD;
      type (anthracycline based [no taxane] vs taxane and anthracyclines vs taxane-based [no&#xD;
      anthracyclines]); and trastuzumab (Herceptin®) timing (concurrently vs sequentially [with&#xD;
      respect to chemotherapy]). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats&#xD;
           every 3 weeks for up to 12 months in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats&#xD;
           every 3 weeks for up to 6 months in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
      All patients also receive standard chemotherapy regimens as per local institutional protocols&#xD;
      either concurrently with or sequentially to trastuzumab.&#xD;
&#xD;
      Patients complete quality of life questionnaires using the EuroQoL-5D (EQ-5D) at baseline and&#xD;
      periodically during study treatment. Patients also complete a diary on out-of-pocket expenses&#xD;
      associated with their condition (i.e., travel expenses, over-the-counter medicines and&#xD;
      supplements, complementary therapies not funded by NHS, home help, and time away from work)&#xD;
      for cost-effective analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 1 year, then&#xD;
      every 6 months for 1 year, and annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness and quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function and analysis of predictive factors for development of cardiac damage</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>parenteral chemotherapy</intervention_name>
    <description>per the local institutional protocols either concurrently with or sequentially to trastuzumab</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer&#xD;
&#xD;
          -  No evidence of metastatic disease&#xD;
&#xD;
          -  Overexpression of HER2 receptor defined as 3+ or 2+ HER2 positivity measured by&#xD;
             fluorescent in situ hybridization (FISH) gene amplification&#xD;
&#xD;
          -  Indication for chemotherapy based on the following clinical and histopathological&#xD;
             features:&#xD;
&#xD;
               -  Receiving or scheduled to receive neoadjuvant chemotherapy&#xD;
&#xD;
                    -  Time between diagnosis biopsy and start date of chemotherapy should be less&#xD;
                       than 1 month&#xD;
&#xD;
               -  Receiving or scheduled to receive adjuvant chemotherapy&#xD;
&#xD;
                    -  Completely resected disease, with negative surgical margins (apart from deep&#xD;
                       margin if full thickness resection)&#xD;
&#xD;
                    -  Marginally resected disease and/or positive sentinel nodes allowed provided&#xD;
                       patients undergo completion of surgery (breast and/or axillary clearance)&#xD;
                       after chemotherapy&#xD;
&#xD;
          -  Hormone receptor status known&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Adequate bone marrow, hepatic, and renal function&#xD;
&#xD;
          -  LVEF normal by ECHO or MUGA&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No clinically significant cardiac abnormalities&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No uncontrolled or malignant hypertension&#xD;
&#xD;
          -  No history of atrioventricular arrhythmia and/or congestive heart failure (even under&#xD;
             medical control), or active second or third degree cardiac block&#xD;
&#xD;
          -  No history of allergy to drugs containing polysorbate 20 and the excipient polysorbate&#xD;
             80 (TWEEN 80®) or history of allergy to mouse proteins&#xD;
&#xD;
          -  No co-morbidity significantly adding to risks associated with cytotoxic chemotherapy&#xD;
             (i.e., severe chronic obstructive pulmonary disease or poorly controlled diabetes)&#xD;
&#xD;
          -  No prior diagnosis of malignancy unless managed by surgical treatment only and&#xD;
             disease-free for 10 years&#xD;
&#xD;
               -  Prior basal cell carcinoma, cervical carcinoma in situ, or ductal carcinoma in&#xD;
                  situ of the breast allowed if treated by surgery only&#xD;
&#xD;
          -  No concomitant medical or psychiatric problems that might preclude completion of&#xD;
             treatment or follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  Concurrent radiotherapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Earl, MBBS, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Earl, MBBS, PhD, FRCP</last_name>
      <phone>44-1223-336-800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cumberland Infirmary</name>
      <address>
        <city>Carlisle</city>
        <state>England</state>
        <zip>CA2 7HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1228-523-444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derbyshire Royal Infirmary</name>
      <address>
        <city>Derby</city>
        <state>England</state>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1332-347-141 ext. 2407</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastbourne District General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <state>England</state>
        <zip>BN21 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1323-417-400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luton and Dunstable Hospital</name>
      <address>
        <city>Luton</city>
        <state>England</state>
        <zip>LU4 0DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-845-127-0127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-151-334-1155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>England</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1642-850-850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1923-826-111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peterborough Hospitals Trust</name>
      <address>
        <city>Peterborough</city>
        <state>England</state>
        <zip>PE3 6DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1733-874-510</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <state>England</state>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-190-230-7999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-84-5456-6000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>September 1, 2011</last_update_submitted>
  <last_update_submitted_qc>September 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

